# A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes

> **NCT06871761** · PHASE3 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 393 (actual)

## Conditions studied

- Adult Patients With Type 2 Diabetes

## Interventions

- **DRUG:** HR17031 injection
- **DRUG:** insulin glargine

## Key facts

- **NCT ID:** NCT06871761
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-08
- **Primary completion:** 2025-05-13
- **Final completion:** 2025-05-13
- **Target enrollment:** 393 (ACTUAL)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06871761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06871761, "A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06871761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*